You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Patent: 10,160,812

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,160,812
Title:Bispecific HER2 antibodies
Abstract: The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.
Inventor(s): Li; John (Gaithersburg, MD), Dimasi; Nazzareno (Gaithersburg, MD), Coats; Steven (Gaithersburg, MD), Damschroder; Melissa (Gaithersburg, MD), Gao; Changshou (Gaithersburg, MD), Rainey; Godfrey (Gaithersburg, MD), Gao; Cuihua (Gaithersburg, MD), Toader; Dorin (Gaithersburg, MD), Gingipalli; Lakshmaiah (Waltham, MA), Wang; Fengjiang (Gaithersburg, MD), Fleming; Ryan (Gaithersburg, MD), Bezabeh; Binyam (Gaithersburg, MD), Yuan; Andy Qingan (Monmouth, NJ), Kasturirangan; Srinath (Gaithersburg, MD)
Assignee: MedImmune, LLC (Gaithersburg, MD)
Application Number:15/302,018
Patent Claims:see list of patent claims

Details for Patent 10,160,812

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial MedImmune, LLC (Gaithersburg, MD) 2034-04-11 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial MedImmune, LLC (Gaithersburg, MD) 2034-04-11 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial MedImmune, LLC (Gaithersburg, MD) 2034-04-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.